Related Experiment Video
Updated: May 19, 2026
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
The aspirin controversy in primary prevention
Nina C Raju1, John W Eikelboom
1Haematology Unit, Pathology Queensland and Internal Medicine Unit, The Prince Charles Hospital, Brisbane, Australia. Nina_Raju@health.qld.gov.au
Insights
Aspirin use for primary prevention of cardiovascular disease reduces heart attacks but increases bleeding risk. Individualized decisions are recommended, balancing benefits against risks for patients.
Area of Science:
- Cardiology
- Preventive Medicine
- Clinical Pharmacology
Background:
- Conflicting meta-analysis results on aspirin's role in primary cardiovascular disease prevention necessitate a critical evaluation.
- Previous meta-analyses, including the 2002 Antithrombotic Trialists' Collaboration, indicated aspirin reduces cardiovascular events, primarily nonfatal myocardial infarction (MI).
Purpose of the Study:
- To review and critically evaluate meta-analysis results comparing aspirin with placebo for primary cardiovascular disease prevention.
- To determine if aspirin provides a net benefit in primary cardiovascular disease prevention.
Main Methods:
- Review of four independent meta-analyses conducted between 2009 and 2012.
- Inclusion of studies involving a large population (95,000–102,621 individuals) at low risk for cardiovascular disease.
Main Results:
- Consistent findings across meta-analyses show aspirin reduces nonfatal myocardial infarction (MI).
- No definitive evidence supports aspirin reducing cardiovascular mortality, though a modest reduction in all-cause mortality is suggested.
- Aspirin decreases ischemic stroke risk but increases hemorrhagic stroke and major bleeding events.
Conclusions:
- In low-risk individuals, aspirin use reduces MI risk but increases major bleeding.
- A modest, nominally significant reduction in total mortality is observed with aspirin.
- Individualized recommendations for aspirin in primary prevention are crucial, considering patient-specific benefits, risks, values, and preferences.
Purpose Of Review:
Apparently conflicting meta-analysis results have led to renewed debate about the role of aspirin for the primary prevention of cardiovascular disease. We review the results of meta-analyses comparing aspirin with placebo or no aspirin for the primary prevention of cardiovascular disease and critically evaluate whether aspirin provides a net benefit.
Recent Findings:
The results of four independently conducted meta-analyses between 2009 and 2012 involving between 95 000 and 102 621 individuals at low risk of cardiovascular disease are consistent with the results of the 2002 Antithrombotic Trialists' Collaboration meta-analysis, which found that aspirin reduces cardiovascular events primarily by reducing nonfatal myocardial infarction (MI). There is no convincing evidence that aspirin reduces cardiovascular mortality, but estimates from all of the meta-analyses suggest a modest reduction in all-cause mortality. Aspirin reduces ischaemic stroke but increases haemorrhagic stroke and major bleeding.
Summary:
The meta-analysis results consistently indicate that, in individuals at low risk for cardiovascular disease, aspirin reduces the risk of MI at the cost of an increase in major bleeding and produces a modest nominally significant reduction in total mortality. These results suggest that recommendations for primary prevention with aspirin should be individualized, taking into account the balance between benefits and risks and individual values and preferences.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:26Atherosclerosis III: Management
01:27Coronary Artery Disease V: Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...